Purpose of the study Short-term antiretroviral therapy (START) consisting of 2 NRTIs and a ritonavir boosted PI is widely used in pregnancy. Resistance is rarely detected using population based sequencing. The aim of this study was to determine whether minority M184V variants emerge with 3TC/FTC containing START regimens in pregnancy and if so whether this impacted upon future treatment outcomes.
Methods
Multi-centre study. An allele-specific real time PCR (ASPCR), optimized for subtypes B, C and AG, was used to detect minority M184V variants. Participants took START for the prevention of HIV mother-to-child transmission (PMTCT). All received standard dose LPVr. Plasma samples were tested pre and post treatment. Routine population based sequencing was also performed.
Summary of results
ASPCR failed in 13/31 (42%) women. Among the remaining 18, 11(61%) were wild type (WT) and 7 (22.5%) had minority M184V sequences (range of detection 0.5 to 14%). All samples were WT with population based sequencing. ASPCR failed to amplify from pretreatment samples in 4/7 women with minority M184V and was WT in 3. Table 1 compares women with and without M184V mutants detected by ASPCR. Therapeutic drug monitoring (TDM) was performed in a subset.
Conclusions
M184V mutants were detected after LPVr based START for PMTCT in 22.5% women. No difference in prior ART, START duration, drug concentration or virological suppression was observed. The presence of minority M184V variants post-partum did not affect future treatment success. The possible association with HIV-1 subtype C requires further evaluation but clade effect on the development of resistance has been reported following intra-partum nevirapine. 
